BridgeBio Pharma (NASDAQ:BBIO) has reached a pivotal turning point following the FDA approval of Attruby (acoramidis), an oral therapy for the rare heart condition transthyretin amyloidosis cardiomyopathy (ATTR-CM). The decision positions the biotech firm for a direct market challenge against Pfizer’s long-standing dominance in the space.
The approval and subsequent commercial momentum have prompted multiple Wall Street firms to raise their price targets on the stock. Mizuho Securities increased its target to $106 from $91, reiterating an Outperform rating. The firm highlighted Attruby’s commercial trajectory, pipeline progress, and an upcoming patent litigation against Pfizer as key catalysts. William Blair also initiated coverage with an Outperform rating, noting that BridgeBio now occupies a “unique position” as a commercial-stage biotechnology company.
Attruby’s approval positions it as a direct competitor to Pfizer’s blockbuster franchise Vyndamax/Vyndaqel (tafamidis), which has amassed nearly $4 billion in annual sales since its 2019 approval but is approaching the end of its core patent exclusivity.
BridgeBio has set the list price for Attruby at $18,759 for a 28-day supply, aligning closely with the approximate $225,000 annual list price of Pfizer’s therapy before discounts. A key differentiator lies in the labeling; Attruby’s FDA-approved label emphasizes its ability to achieve “near-complete stabilization of TTR,” a distinction that could resonate with physicians and patients. The approval was supported by the Phase III ATTRibute-CM trial, where Attruby demonstrated a 42% reduction in the composite endpoint of all-cause mortality and recurrent cardiovascular-related hospitalizations at 30 months.
Several analysts project Attruby could achieve peak annual sales ranging from $2 billion to $4 billion if market adoption is successful. However, competition is intensifying. Alnylam’s RNAi therapy vutrisiran (Amvuttra) is expected to receive an approval decision for ATTR-CM next year, offering a subcutaneous injection administered once every three months—a potential convenience advantage over oral drugs. AstraZeneca and Ionis’ eplontersen (Wainua) is also a contender in the space.
Beyond commercial execution, the market is closely watching the upcoming patent litigation involving Pfizer’s tafamidis. Mizuho noted that a bench trial scheduled from April 27 to May 1 could materially impact BridgeBio’s stock. A favorable outcome, analysts suggest, could add considerable value, with every additional $1 billion in peak sales representing a significant upside.
BridgeBio has already secured strategic partnerships to support Attruby’s global rollout. Bayer secured European rights with a $310 million upfront and near-term payment, with BridgeBio eligible for tiered royalties in the “low-thirties” percentage range. AstraZeneca licensed Japanese rights for the drug. Additionally, in a move to optimize its financial structure, the company sold a 5% royalty stake on Attruby for $500 million in January.
With Attruby now entering the commercial phase, BridgeBio is transitioning from a clinical-stage developer to a commercial entity poised to compete directly with pharmaceutical giants in the rare disease space.
